Search - tctmd.com

Displaying 101 - 120 of 367

Sort: Relevancy | Date

Presentation TCT 2022

TCT 64: FANTOM II Long Lesion Study: Initial Safety & Performance Study of the Fantom Sirolimus-Eluting Bioresorbable Coronary Scaffold in Long Lesions – 3 Clinical Year Outcomes

Presenter: Matthias Lutz

September 17, 2022

Presentation TCT 2022

TCT 58: FANTOM II Trial: Safety & Performance Study of the Fantom Sirolimus-Eluting Bioresorbable Coronary Scaffold – Final: 5 Year Clinical Outcomes

Presenter: Matthias Lutz

September 17, 2022

Presentation TCT 2022

Sirolimus DCBs: Technological Trends, Challenges and Advantages

Presenter: Ron Waksman

September 17, 2022

Presentation TCT 2022

Sirolimus Coated DCB in All-Comers EASTBOURNE (MagicTouch DCB)

Presenter: Bernardo Cortese

September 17, 2022

News Industry News

TRANSFORM 1 Enrollment Completed: A Crucial RCT ready to redefine the DCB Angioplasty Mechanism

September 13, 2022

News Conference News EuroPCR 2022

Shorter DAPT Sufficient Even in Complex HBR Patients: MASTER DAPT

Yael L. Maxwell

May 17, 2022

News Conference News

BIOFLOW V: Orsiro Still Offers Some Benefits at 5 Years

Caitlin E. Cox

March 02, 2022

News Conference News TCT 2021

DCBs in Coronaries? Some Good News, but More Work Needed

L.A. McKeown

November 06, 2021

Presentation TCT 2021

One-year Outcomes of Two Parallel Randomized Trials of Sirolimus-Coated and Paclitaxel-Coated Balloons in Coronary In-Stent Restenosis Lesions

Presenter: Bruno Scheller

November 06, 2021

Presentation TCT 2021

A Randomized Trial of Sirolimus-coated Versus Paclitaxel-coated Balloons in De Novo Coronary Lesions

Presenter: Wan Azman Wan Ahmad

November 06, 2021

Presentation TCT 2021

The MAGICAL trial – Insights from the upcoming US IDE DCB study

Presenter: Martin Leon

November 05, 2021

News Conference News TCT 2021

‘Sweet Like SUGAR’: Polymer-Free Stent Noninferior to ZES in Diabetic Patients

Yael L. Maxwell

November 04, 2021

Presentation TCT 2021

FANTOM II Trial: Safety & Performance Study of the Fantom Sirolimus-Eluting Bioresorbable Coronary Scaffold – First Report: Final 5 Year Clinical Outcomes

Presenter: Matthias Lutz

November 04, 2021

News Conference News TCT 2021

OPTIMIZE: 2-Year DES Data Affirm Need for Meaningful MI Definitions

L.A. McKeown

October 25, 2021

News Conference News TCT 2021

Good Long-term Results With FANTOM BVS, but More Data Needed

Michael O'Riordan

October 21, 2021

News Daily News

Cardiac Deaths and Adverse Events After PCI Have Declined With Time

L.A. McKeown

October 05, 2021

News Conference News ESC 2021

OAC Analysis From MASTER DAPT Raises No Red Flags for Shorter DAPT

Shelley Wood

September 02, 2021

News Conference News ESC 2021

MASTER DAPT: One Month's Enough in Patients at High Bleeding Risk

Shelley Wood

August 28, 2021

News Conference News EuroPCR 2021

Ultrathin Orsiro Performs Well in All-Comers, Interim CASTLE Data Indicate

Caitlin E. Cox

May 24, 2021

News Conference News EuroPCR 2021

FUTURE II: A Good ‘First Step’ for Thinner-Strut Bioresorbable Scaffold

Michael O'Riordan

May 19, 2021

Advertisement

TCT 64: FANTOM II Long Lesion Study: Initial Safety & Performance Study of the Fantom Sirolimus-Eluting Bioresorbable Coronary Scaffold in Long Lesions – 3 Clinical Year Outcomes

TCT 58: FANTOM II Trial: Safety & Performance Study of the Fantom Sirolimus-Eluting Bioresorbable Coronary Scaffold – Final: 5 Year Clinical Outcomes

Sirolimus DCBs: Technological Trends, Challenges and Advantages

Sirolimus Coated DCB in All-Comers EASTBOURNE (MagicTouch DCB)

TRANSFORM 1 Enrollment Completed: A Crucial RCT ready to redefine the DCB Angioplasty Mechanism

Shorter DAPT Sufficient Even in Complex HBR Patients: MASTER DAPT

BIOFLOW V: Orsiro Still Offers Some Benefits at 5 Years

DCBs in Coronaries? Some Good News, but More Work Needed

One-year Outcomes of Two Parallel Randomized Trials of Sirolimus-Coated and Paclitaxel-Coated Balloons in Coronary In-Stent Restenosis Lesions

A Randomized Trial of Sirolimus-coated Versus Paclitaxel-coated Balloons in De Novo Coronary Lesions

The MAGICAL trial – Insights from the upcoming US IDE DCB study

‘Sweet Like SUGAR’: Polymer-Free Stent Noninferior to ZES in Diabetic Patients

FANTOM II Trial: Safety & Performance Study of the Fantom Sirolimus-Eluting Bioresorbable Coronary Scaffold – First Report: Final 5 Year Clinical Outcomes

OPTIMIZE: 2-Year DES Data Affirm Need for Meaningful MI Definitions

Good Long-term Results With FANTOM BVS, but More Data Needed

Cardiac Deaths and Adverse Events After PCI Have Declined With Time

OAC Analysis From MASTER DAPT Raises No Red Flags for Shorter DAPT

MASTER DAPT: One Month's Enough in Patients at High Bleeding Risk

Ultrathin Orsiro Performs Well in All-Comers, Interim CASTLE Data Indicate

FUTURE II: A Good ‘First Step’ for Thinner-Strut Bioresorbable Scaffold

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content